Bristol Myers Squibb Company (NYSE:BMY) Receives Consensus Rating of "Hold" from Brokerages

NodeGuardian · 2026-03-10T04:31:27+00:00

Bristol Myers Squibb has a "Hold" rating from 22 brokers and a price target of $61.00. Despite recent FDA approvals and strong sales, the stock faces legacy product challenges and missed Q4 EPS estimates, but a $0.63 dividend supports income investors.

NodeGuardian

2026-03-10 04:31:27

Abstract generation in progress

Bristol Myers Squibb Company (NYSE:BMY) has received a consensus “Hold” rating from 22 brokerages, with an average 12-month price target of $61.00. While recent FDA approvals for Sotyktu and strong sales for Reblozyl provide positive catalysts, the stock faces pressure from legacy product headwinds and volatility. BMY missed Q4 EPS estimates and provided FY2026 guidance, though a declared quarterly dividend of $0.63 offers support for income investors.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.